Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68-DOTA-TOC PET/MR in Small Bowel Carcinoid Tumors
NCT03057509Phase 1Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2018
- Primary completion
- Oct 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga 68-edotreotide in small bowel carcinoid tumor, sponsored by Massachusetts General Hospital. Primary endpoints: Mean Change in SUVmax at 2 years and Mean Change in Total Molecular Burden of The Lesions at 2 years. Planned start Nov 2018; status: withdrawn.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
small bowel carcinoid tumor
Beyond the preview
Go deeper on NCT03057509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057509.